Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Whalewatcher1on Oct 06, 2019 3:28pm
132 Views
Post# 30201404

RE: ANATOMY OF A GRIFTER

RE: ANATOMY OF A GRIFTERLooks le the insiders are the only ones who win
- Chris Moreau is CEO of Algernon and was currently CEO of First Responders. He was also CEO of Nash Pharma. Nash gives him $1M in stock just before trying to close current financing. The CEO and CSO of Algernon were also board members of NASH while I'd was private, Moreau had a Williams the CEO role for a few months to finalize the acquisition. guess what, Bill Run group also controlling shareholder. Thus Bull Rub controls Algernon, controller Nash Pharma and First responders and does self serving dealing? I sure hope the new investors understand all the dealings. This is b.s

AMG, thanks for pointing this all out. I imagine the more one digs, the more issues will come up. Can't believe Mackie Research didn't complete their diligence before current offering, or maybe this is cause for delay




Bullboard Posts